No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ONCT Oncternal Therapeutics
- 8.0000
- -0.2300-2.79%
Close Jun 18 16:00 ET
- 8.3300
- +0.3300+4.13%
Post 16:17 ET
23.68MMarket Cap-648P/E (TTM)
8.4205High8.0000Low3.91KVolume8.2100Open8.2300Pre Close32.13KTurnover0.15%Turnover RatioLossP/E (Static)2.96MShares13.140052wk High1.03P/B21.65MFloat Cap5.565652wk Low--Dividend TTM2.71MShs Float3583.9949Historical High--Div YieldTTM5.11%Amplitude5.2200Historical Low8.2140Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Here's Why Shareholders May Want To Be Cautious With Increasing Oncternal Therapeutics, Inc.'s (NASDAQ:ONCT) CEO Pay Packet
Key Insights Oncternal Therapeutics' Annual General Meeting to take place on 20th of June Salary of US$609.4k is part of CEO Jim Breitmeyer's total remuneration The overall pay is 44% above the in
Analysts Offer Insights on Healthcare Companies: Springworks Therapeutics (SWTX), Cyclo Therapeutics (CYTH) and Oncternal Therapeutics (ONCT)
Express News | HC Wainwright & Co. Reiterates Buy on Oncternal Therapeutics, Maintains $19 Price Target
Express News | Oncternal to Provide Onct-534 Study Update Q3 2024
Express News | Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of Onct-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
Oppenheimer Remains a Hold on Oncternal Therapeutics (ONCT)
Comments
$Oncternal Therapeutics(ONCT.US$
Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
1
$Oncternal Therapeutics(ONCT.US$ Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of Onct-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
$Oncternal Therapeutics(ONCT.US$ Oncternal Therapeutics Enrolls Patients In Third Dosing Cohort Of Phase 1/2 Study Of ONCT-534![]()
1
$Oncternal Therapeutics(ONCT.US$ Oncternal Therapeutics Announces FDA Granted Fast Track Designation for ONCT-534 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
5 MINUTES AGO, 9:00 AM EDT
VIA GLOBENEWSWIRE![]()
5 MINUTES AGO, 9:00 AM EDT
VIA GLOBENEWSWIRE
Dr. Smith's advisory role will help shape the clinical strategy for ONCT-534. Her expectation is that the drug could deal with escape mechanisms of a specific prostate cancer, boosting its prospective efficiency and market validity.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg